Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study
Journal
Cancer
Journal Volume
129
Journal Issue
8
Date Issued
2023-04-15
Author(s)
Oh, Do-Youn
Algazi, Alain
Capdevila, Jaume
Longo, Federico
Miller, Wilson
Chun Bing, Jerry Tan
Bonilla, Carlos Eduardo
Chung, Hyun Cheol
Guren, Tormod K
Motola-Kuba, Daniel
Shah, Manisha
Hadoux, Julien
Yao, Lili
Jin, Fan
Norwood, Kevin
Lebellec, Loïc
Abstract
The authors report results from the thyroid carcinoma cohort of the multicohort phase 2 KEYNOTE-158 study (NCT02628067), which evaluated pembrolizumab monotherapy in patients with previously treated cancers.
Subjects
immunotherapy; pembrolizumab; programmed cell death 1 ligand 1; programmed cell death 1 receptor; thyroid neoplasms
SDGs
Type
journal article